Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift? [PDF]
Dono F +6 more
europepmc +1 more source
Individual Alpha Frequency as an EEG Biomarker of Drug-Related Cognitive Burden in Epilepsy. [PDF]
Assenza G +10 more
europepmc +1 more source
Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: A real-world retrospective study in Spain. [PDF]
Sánchez-Caro JM +3 more
europepmc +1 more source
Early antiseizure response to cenobamate (200 mg/day) in focal drug-resistant epilepsy: a retrospective single-center analysis. [PDF]
Czapińska-Ciepiela E +3 more
europepmc +1 more source
Cenobamate: A comprehensive review
David G Vossler, Raman Sankar
openaire +1 more source
Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy
Objectives: Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SCN8A are associated with difficult-to-treat and early-onset seizures, developmental delay/intellectual disability, impaired quality of life, and increased ...
Ricci, Emilia +15 more
core
Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System. [PDF]
Shang S +10 more
europepmc +1 more source
Antiseizure Treatments and Liver Injury: Expect (and Prevent) the Unexpected. [PDF]
Bunch M +4 more
europepmc +1 more source
Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review. [PDF]
Samanta D.
europepmc +1 more source

